Catena Biosciences

Based in Berkeley, California, Catena Biosciences is a biotechnology company that develops novel therapeutics by utilizing oxidative protein coupling to conjugate proteins with targeting molecules for accelerated drug creation. The proprietary technology enables the engineering of complex biological treatments, focusing on CRISPR base editors, specialized antibodies, and cell-based therapies directed at oncology and autoimmune diseases. Operating with a core team of 7 employees, the organization achieved a valuation exceeding $10 million during its initial venture capital financing rounds in 2021. The firm secured institutional backing from the startup accelerator Y Combinator and leverages foundational scientific research originating from UC Berkeley. To support its clinical pipeline, the company recruited industry veterans Saurabh Johri and Rick Kendall to its executive leadership team. Catena Biosciences was founded in 2020 by Matthew Francis and Marco Lobba.

High-Level Overview

Catena Biosciences is a biotechnology company pioneering a novel protein coupling technology that enables the attachment of any two proteins together using an enzyme and native amino acids (tyrosine and cysteine). This platform technology allows the creation of modular protein therapeutics rapidly and with high selectivity, overcoming limitations of traditional genetic fusion or chemical attachment methods. Catena’s technology is applied across multiple therapeutic areas including oncology, autoimmune diseases, vaccines, and gene editing delivery systems such as CRISPR. Their approach facilitates the development of complex, multi-payload conjugates that can improve efficacy and safety profiles of targeted therapies, particularly in cancer treatment[1][2][5].

For an investment firm, Catena represents a cutting-edge biotech innovator focused on next-generation protein therapeutics with a platform that accelerates drug development and expands therapeutic possibilities. Their impact on the startup ecosystem lies in advancing protein conjugation science, enabling new classes of biologics, and addressing unmet medical needs in autoimmune and cancer therapies.

For a portfolio company, Catena builds a proprietary protein conjugation platform (CysTyr®) and develops Multi-Payload Conjugates (MPC®) that serve pharmaceutical developers and patients by solving the problem of delivering complex, targeted combination therapies with improved stability and selectivity. The company has demonstrated growth momentum through successful preclinical results, presentations at major scientific conferences, and recognition in biotech innovation circles[1][5][8].

---

Origin Story

Catena Biosciences was founded in 2020 by Marco Lobba, Matthew Francis, and Geo Guillen, with roots in the University of California, Berkeley. Marco Lobba, the CEO, completed his Ph.D. jointly in the labs of Matt Francis and Nobel laureate Jennifer Doudna, where the foundational protein conjugation technology was developed. The idea emerged from the challenge of delivering complex biologics like CRISPR systems and targeted cancer therapies, where traditional conjugation methods were insufficient. Early traction included demonstrating the ability to build CRISPR base editors and modifying cancer-specific antibodies, which validated the platform’s broad applicability and therapeutic potential[1][3].

---

Core Differentiators

• Platform Technology: Catena’s CysTyr® platform uses a proprietary enzyme (Catenase®) to form a stable C-Y bond between tyrosine and cysteine residues, enabling precise, selective, and stable protein conjugation without artificial functional groups or bulky domains[5][6].
• Versatility: The technology can join any two soluble proteins regardless of size or complexity, allowing creation of novel therapeutic constructs beyond the reach of genetic fusion or chemical methods[2][9].
• Multi-Payload Conjugates (MPC®): Enables attachment of multiple distinct payloads on a single antibody, allowing combination therapies that can overcome tumor resistance and improve efficacy and safety[5][8].
• Speed and Scalability: The enzymatic process allows rapid production of modular protein therapeutics, facilitating library creation and accelerating drug discovery timelines[1][6].
• Improved Stability: The C-Y bond formed is more stable in serum than traditional linkages, potentially enhancing therapeutic safety and effectiveness[5].
• Broad Therapeutic Applications: From oncology and autoimmune diseases to vaccines and gene editing delivery, Catena’s platform supports diverse drug modalities[1][3][4].

---

Role in the Broader Tech Landscape

Catena Biosciences rides the growing trend of precision biologics and targeted protein therapeutics, addressing critical challenges in drug delivery and combination therapies. The timing is favorable due to increasing demand for more effective cancer treatments, autoimmune disease therapies, and advanced gene editing delivery systems. Market forces such as the rise of antibody-drug conjugates (ADCs), the need for multi-mechanism therapies to overcome resistance, and the push for scalable, modular biologics development work in Catena’s favor. By enabling novel protein conjugations, Catena influences the biotech ecosystem by expanding the toolkit available for therapeutic design, potentially accelerating innovation across multiple disease areas[5][9].

---

Quick Take & Future Outlook

Looking ahead, Catena Biosciences is poised to advance its pipeline of Multi-Payload Conjugates through further preclinical and clinical development, particularly targeting solid tumors with high unmet needs. Trends such as personalized medicine, combination therapies, and biologics innovation will shape their journey. Their platform’s ability to create previously impossible therapeutic structures suggests growing influence in both biotech R&D and clinical applications. As they demonstrate clinical efficacy and safety, Catena could become a key player in next-generation protein therapeutics, driving new standards for targeted, multi-modal treatments that improve patient outcomes[5][8].

This trajectory ties back to their foundational innovation in protein coupling, which continues to unlock new therapeutic possibilities beyond traditional biologics.